New PhIII data for Stelara and IV Simponi back expansion of Janssen's arthritis franchise
This article was originally published in Scrip
Janssen Research & Development will present data at the American College of Rheumatology (ACR) Scientific Sessions in Washington, DC that could play a role in expanding the Johnson & Johnson subsidiary's arthritis franchise with a new indication for Stelara (ustekinumab) and an intravenous version of Simponi (golimumab).
You may also be interested in...
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.